DexCom, Inc. (DXCM)
Summary
Pharmsource says it was unaware Dexcom sensors it bought were slated for destruction
Drug wholesaler Pharmsource LLC said it was unaware the Dexcom glucose sensors it bought from licensed distributors had been slated for destruction, after the device maker warned some units were stolen during disposal and resold.
Why DexCom (DXCM) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
DexCom Reports Positive CONNECT Data for Non-Insulin Diabetes
DXCM reports positive CONNECT trial results as Dexcom G7 improves HbA1c and time in range in adults with Type 2 diabetes not using insulin.
DexCom, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Texas Capital Bancshares Inc. Texas Capital Bancshares Inc. | 8 | $538 | $589.68 | $51.68 | 9.61% |
 Bridgewater Associates LP Bridgewater Associates LP | 139,687 | $11.59M | $10.3M | -$1.29M | -11.14% |
 Douglas Silverman Senator Investment Group LP | 105,626 | $11.99M | $7.79M | -$4.2M | -35.06% |
 Point72 Asset Management LP Point72 Asset Management LP | 257,298 | $17.31M | $18.98M | $1.66M | 9.62% |
| RR rosemary richard WCG Wealth Advisors LLC | 30,734 | $2.04M | $2.27M | $232,041.7 | 11.38% |
DexCom, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| DA Danielle Antalffy UBS | 84.11 | $5,731.9 | $6,218.88 | $486.98 | 8.5% |
| JJ Joshua Jennings TD Cowen | 170.47 | $10,966.42 | $12,597.39 | $1,630.97 | 14.87% |
| MO Matt O'Brien Piper Sandler | 14.69 | $890.1 | $1,085.72 | $195.62 | 21.98% |
| MT Marie Thibault BTIG | 71.81 | $5,104.75 | $5,297.44 | $192.69 | 3.77% |
| WP William Plovanic Canaccord Genuity | 51.91 | $3,377.81 | $3,832.77 | $454.96 | 13.47% |
DexCom, Inc. (DXCM) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has DexCom, Inc. ever had a stock split?
DexCom, Inc. Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Jacob Steven Leach CEO | NASDAQ (NGS) Exchange | 252131107 CUSIP |
| US Country | 10,200 Employees | - Last Dividend | 13 Jun 2022 Last Split | 14 Apr 2005 IPO Date |
Overview
DexCom, Inc. is an innovative medical device company with a strong focus on the design, development, and commercialization of continuous glucose monitoring (CGM) systems. Founded in 1999 and based in San Diego, California, DexCom has made significant strides in providing state-of-the-art diabetes management solutions. Their products cater to both individuals with diabetes and healthcare providers, offering advanced technology for continuous glucose tracking both in the United States and internationally. Through strategic collaborations, including agreements with Verily Life Sciences LLC and Verily Ireland Limited, DexCom continues to pioneer in the pursuit of enhancing diabetes care with the aim of developing new glucose monitoring products. The company's approach to directly market its innovations to endocrinologists, physicians, and diabetes educators underscores their commitment to integrating their systems into the healthcare community, thereby ensuring they meet the needs of their end-users effectively.
Products and Services
- Dexcom G6 and Dexcom G7: These integrated CGM systems are designed for comprehensive diabetes management. They allow users to monitor their glucose levels continuously without the need for routine finger pricks. By providing real-time glucose data, the Dexcom G6 and G7 help individuals with diabetes maintain better control over their condition.
- Dexcom Share: This service facilitates remote monitoring, enabling users to share their glucose data with up to five followers. Dexcom Share is especially beneficial for caregivers who need to monitor the glucose levels of loved ones, adding a layer of safety and peace of mind for both the users and their families.
- Dexcom Real-Time API: With this offering, DexCom opens the door for authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices. This connectivity enhances the ecosystem of diabetes management tools, allowing for more personalized and efficient care plans.
- Dexcom ONE: Aimed at simplifying diabetes management, Dexcom ONE is designed to replace fingerstick blood glucose testing entirely for treatment decisions. This product targets a broader audience, making CGM technology more accessible to those who may benefit from continuous glucose insights without the traditional hassles of blood glucose testing.
- Dexcom Stelo: Currently under FDA review, Dexcom Stelo is geared toward individuals with type 2 diabetes. This addition to DexCom's product line underscores the company's continuous effort to cater to the diverse needs of the diabetes community, aiming to simplify and improve the quality of diabetes care across the board.
